相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells
S. Hiscox et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors
Yi Chen et al.
CLINICAL CANCER RESEARCH (2009)
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Tim P. Green et al.
MOLECULAR ONCOLOGY (2009)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pharmacodynamic markers of perifosine efficacy
Bryan T. Hennessy et al.
CLINICAL CANCER RESEARCH (2007)
Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer
Stephen R. D. Johnston et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Non-parametric quantification of protein lysate arrays
Jianhua Hu et al.
BIOINFORMATICS (2007)
Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer
Isabel Chu et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2
Isabel Chu et al.
CELL (2007)
Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases
Matthias Grimmler et al.
CELL (2007)
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells
Matthew H. Herynk et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
Raoul Tibes et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
SRD Johnston et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
A Howell et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The role of Shc and insulin-like qrowth factor 1 receptor in mediating the translocation of estrogen receptor a to the plasma membrane
RX Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src
PA Plé et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action
G Castoria et al.
JOURNAL OF CELL BIOLOGY (2003)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells
G Castoria et al.
EMBO JOURNAL (2001)
Intracellular signaling pathways: Nongenomic actions of estrogens and ligand-independent activation of estrogen receptors
KM Coleman et al.
FRONTIERS IN BIOSCIENCE (2001)
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
AP Belsches-Jablonski et al.
ONCOGENE (2001)
Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation
A Migliaccio et al.
EMBO JOURNAL (2000)
Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
S Cariou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
